Gurugram (Haryana) [India], November 7 (ANI): In a significant breakthrough for healthcare in India, doctors at FMRI in Gurugram have achieved remarkable success in treating children with Sickle Cell Disease (SCD) through Bone Marrow (stem cell) transplantation. This advancement positions India among the top countries in pediatric transplant outcomes. A decade-long study, published in the international journal Haemoglobin, examined 100 pediatric cases treated between 2015 and 2024. The findings indicate an overall survival rate of around 87%, with matched sibling donor transplants achieving a 96% success rate and haploidentical family donor transplants showing a 78% success rate. These results are among the best globally and represent a significant improvement in managing Sickle Cell Disease in developing countries.
Sickle Cell Disease is an inherited blood disorder that impacts millions of children worldwide, particularly in India and sub-Saharan Africa, where nearly half of the cases exist. The disorder leads to severe anemia, recurrent pain crises, strokes, organ damage, and a reduced life expectancy. Previously, treatment options were largely limited to managing symptoms through medications and blood transfusions. Stem cell transplantation replaces defective bone marrow with healthy stem cells from a compatible donor, providing a potential cure.
Dr. Swati Bhayana, lead author of the study and consultant in Pediatric Hematology, Oncology, and Bone Marrow Transplant at Fortis Gurugram, remarked, “This is a ray of hope for families living with Sickle Cell Disease. Our research shows that children in developing countries like India and across Africa can achieve survival rates comparable to the best centers in the world when given timely access to advanced care. These results prove that a cure is possible, even in resource-limited settings.”
The study emphasized that early diagnosis and timely transplants are essential for long-term survival. Performing the transplant before serious complications, such as strokes or organ damage, significantly enhances outcomes. The Fortis team utilized advanced transplant protocols to minimize side effects and lower the risk of graft-versus-host disease (GVHD), a common complication post-transplant.
Dr. Vikas Dua, Principal Consultant & Head of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Fortis Gurugram, added, “Many of these children had been suffering from pain, frequent hospitalizations, and dependence on transfusions. Today, they are living healthy, active lives. This milestone reinforces our belief that every child deserves a chance at a normal life and that early intervention is key to success.”
Moreover, the study highlighted progress in haploidentical (half-matched) transplants that use parental donors when a full sibling match is not available. The implementation of reduced-toxicity conditioning and post-transplant cyclophosphamide (PTCy) protocols has decreased complication rates, making the treatment safer and more broadly applicable.
Dr. Rahul Bhargava, Principal Director at the Institute of Blood Disorders and Bone Marrow Transplant, underscored the wider implications: “India and Africa together account for nearly half of the world’s burden of Sickle Cell Disease. By developing cost-effective, safe, and scalable transplant protocols, we are demonstrating that cutting-edge medical innovation can extend beyond the developed world. Our aim is to ensure that every child, irrespective of geographical location or income, has access to a cure.”
Dr. Sohini Chakraborty, Senior Consultant in Pediatric Hematology, Oncology, and Bone Marrow Transplant at Fortis Gurugram, remarked, “The findings underscore the importance of awareness, collaboration, and early diagnosis. With improved donor registries, better infection control, and robust post-transplant care, we are optimistic that a cure for Sickle Cell Disease can become a reality for children globally.”
Yashpal Rawat, VP & Facility Director at Fortis Gurugram, stated, “At Fortis, we believe that innovation should serve humanity. This breakthrough reflects our mission to combine world-class technology with compassion, ensuring lifesaving treatments are accessible and affordable for families in India, Africa, and beyond. The success of this decade-long effort symbolizes not only medical excellence but also Fortis Healthcare’s commitment to broadening access to advanced care across regions.”
This achievement signifies a notable milestone for Indian healthcare.
Original Source: https://www.aninews.in/news/national/general-news/research-institute-at-gurugram-reveals-breakthrough-in-treating-children-with-sickle-cell-disease-via-stem-cell-transplant20251108214227/
Category:
Tags:
Publish Date: 2025-11-08 21:42:00
